Powering Relentless Science

EOM Pharmaceuticals is focused on developing and commercializing first-in-class treatments to address urgent and unmet medical needs that help better the quality of life for people with debilitating and potentially fatal diseases, including COVID-19 and other infectious diseases; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS and cancer; and topical non-invasive treatments for sight-robbing retinal diseases.

 

 

 

 

 

 

 

 

 

 

The Legacy and Potential of EOM613

EOM613 is the lead product candidate being developed by EOM Pharmaceuticals. It is an investigational, first-in-class, dual-acting, broad-spectrum immunomodulator designed to have both an anti-inflammatory effect specifically at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect, when needed to restore physiological balance.

Distinct from conventional immunomodulators, which generally target a single process of the immune response either pro- or anti-inflammatory, EOM613 is designed to modulate the body’s fine balance of pro-inflammatory and anti-inflammatory cytokines and chemokines to counteract the most severe inflammatory effects of viruses, such as cytokine storm following infection with the novel coronavirus that causes COVID-19, autoimmune attacks that cause joint damage and pain associated with rheumatoid arthritis, and chemokine-related body-wasting syndromes such as cachexia.

By re-establishing normal physiological immune balance, EOM613 serves to rescue, repair, and restore an immune system that has been confronted by an invading antigen, pathogen, or virus. This dual-acting, broad-spectrum approach may overcome a key limitation of conventional immunomodulators. EOM613 has already demonstrated clinical improvements in various disease states and immune-related biomarkers and general tolerability across five Phase 2 clinical trials in patients with AIDS, cancer cachexia and rheumatoid arthritis. It is administered as a subcutaneous injection, unlike conventional immunomodulators which often require intravenous infusion. EOM613 is efficiently manufactured from readily available materials.

A Unique Mechanism of Action:

Watch how EOM613 may work to re-establish natural balance in an immune system that has been confronted by an invading antigen, pathogen, or virus

The legacy of EOM613 began in World War II when its precursor Reticulose was used successfully to treat soldiers with the flu. It was considered a significant treatment advance at the time and has been studied continuously in the pursuit of realizing its full potential as an anti-viral and now in a new formulation as the first dual-acting, broad-spectrum immunomodulator.

A Historical Timeline of EOM613